Skip to content 
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States. more
| Time Frame | HQL | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 3.81% | 1.74% | 0.74% |
| 1-Month Return | 4.68% | -1.15% | 1.28% |
| 3-Month Return | 1.46% | 2% | 3.6% |
| 6-Month Return | 24.59% | -0.02% | 7.31% |
| 1-Year Return | 22.75% | 0.77% | 11.97% |
| 3-Year Return | 21.63% | 47.56% | 72.07% |
| 5-Year Return | -21.02% | 62.26% | 76.01% |
| 10-Year Return | 0.46% | 208.57% | 258.47% |
| Sep '21 | Sep '22 | Sep '23 | Sep '24 | Sep '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 65.69M | (103.25M) | 23.52M | 86.69M | 86.39M | [{"date":"2021-09-30","value":75.78,"profit":true},{"date":"2022-09-30","value":-119.11,"profit":false},{"date":"2023-09-30","value":27.14,"profit":true},{"date":"2024-09-30","value":100,"profit":true},{"date":"2025-09-30","value":99.65,"profit":true}] |
| Cost of Revenue | 5.60M | 5.55M | 5.24M | - | - | [{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":99.04,"profit":true},{"date":"2023-09-30","value":93.6,"profit":true},{"date":"2024-09-30","value":"-","profit":true},{"date":"2025-09-30","value":"-","profit":true}] |
| Gross Profit | 65.69M | (103.25M) | 23.52M | 86.69M | 86.39M | [{"date":"2021-09-30","value":75.78,"profit":true},{"date":"2022-09-30","value":-119.11,"profit":false},{"date":"2023-09-30","value":27.14,"profit":true},{"date":"2024-09-30","value":100,"profit":true},{"date":"2025-09-30","value":99.65,"profit":true}] |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | [{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":100,"profit":true},{"date":"2024-09-30","value":100,"profit":true},{"date":"2025-09-30","value":100,"profit":true}] |
| Operating Expenses | 1.16M | 1.35M | 1.17M | 1.39M | 791.57K | [{"date":"2021-09-30","value":83.36,"profit":true},{"date":"2022-09-30","value":97.4,"profit":true},{"date":"2023-09-30","value":84.35,"profit":true},{"date":"2024-09-30","value":100,"profit":true},{"date":"2025-09-30","value":57,"profit":true}] |
| Operating Income | 64.53M | (104.60M) | 22.35M | 85.30M | 85.59M | [{"date":"2021-09-30","value":75.39,"profit":true},{"date":"2022-09-30","value":-122.21,"profit":false},{"date":"2023-09-30","value":26.11,"profit":true},{"date":"2024-09-30","value":99.65,"profit":true},{"date":"2025-09-30","value":100,"profit":true}] |
| Total Non-Operating Income/Expense | - | 52.51K | 202.75K | 88.26M | - | [{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":0.06,"profit":true},{"date":"2023-09-30","value":0.23,"profit":true},{"date":"2024-09-30","value":100,"profit":true},{"date":"2025-09-30","value":"-","profit":true}] |
| Pre-Tax Income | 64.53M | (104.60M) | 22.35M | 85.30M | 85.59M | [{"date":"2021-09-30","value":75.39,"profit":true},{"date":"2022-09-30","value":-122.21,"profit":false},{"date":"2023-09-30","value":26.11,"profit":true},{"date":"2024-09-30","value":99.65,"profit":true},{"date":"2025-09-30","value":100,"profit":true}] |
| Income Taxes | (4.15M) | (2.99M) | 22.35M | - | - | [{"date":"2021-09-30","value":-18.55,"profit":false},{"date":"2022-09-30","value":-13.37,"profit":false},{"date":"2023-09-30","value":100,"profit":true},{"date":"2024-09-30","value":"-","profit":true},{"date":"2025-09-30","value":"-","profit":true}] |
| Income After Taxes | - | (101.62M) | (1.70K) | - | - | [{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":-10161539200,"profit":false},{"date":"2023-09-30","value":-170200,"profit":false},{"date":"2024-09-30","value":"-","profit":true},{"date":"2025-09-30","value":"-","profit":true}] |
| Income From Continuous Operations | 64.53M | (104.60M) | 22.35M | 85.30M | 85.59M | [{"date":"2021-09-30","value":75.39,"profit":true},{"date":"2022-09-30","value":-122.21,"profit":false},{"date":"2023-09-30","value":26.11,"profit":true},{"date":"2024-09-30","value":99.65,"profit":true},{"date":"2025-09-30","value":100,"profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true},{"date":"2025-09-30","value":"-","profit":true}] |
| Net Income | 64.53M | (104.60M) | 22.35M | 85.30M | 85.59M | [{"date":"2021-09-30","value":75.39,"profit":true},{"date":"2022-09-30","value":-122.21,"profit":false},{"date":"2023-09-30","value":26.11,"profit":true},{"date":"2024-09-30","value":99.65,"profit":true},{"date":"2025-09-30","value":100,"profit":true}] |
| EPS (Diluted) | 3.94 | (4.11) | - | 1.22 | 2.74 | [{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":-104.36,"profit":false},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":30.98,"profit":true},{"date":"2025-09-30","value":69.57,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| HQL | |
|---|---|
| Cash Ratio | 0.10 |
| Current Ratio | 1.74 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| HQL | |
|---|---|
| ROA (LTM) | -0.43% |
| ROE (LTM) | 17.59% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| HQL | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.00 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 1.00 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| HQL | |
|---|---|
| Trailing PE | 6.27 |
| Forward PE | NM |
| P/S (TTM) | 267.22 |
| P/B | 0.98 |
| Price/FCF | NM |
| EV/R | 5.82 |
| EV/Ebitda | NM |
| PEG | NM |
Tekla Life Sciences Investors (HQL) share price today is $17.43
Yes, Indians can buy shares of Tekla Life Sciences Investors (HQL) on Vested. To buy
Yes, you can purchase fractional shares of Tekla Life Sciences Investors (HQL) via the Vested app. You can start investing in Tekla Life Sciences Investors (HQL) with a minimum investment of $1.
You can invest in shares of Tekla Life Sciences Investors (HQL) via Vested in three simple steps:
The 52-week high price of Tekla Life Sciences Investors (HQL) is $17.7. The 52-week low price of Tekla Life Sciences Investors (HQL) is $9.59.
The price-to-earnings (P/E) ratio of Tekla Life Sciences Investors (HQL) is 6.2724
The price-to-book (P/B) ratio of Tekla Life Sciences Investors (HQL) is 0.98
The dividend yield of Tekla Life Sciences Investors (HQL) is 10.72%
The market capitalization of Tekla Life Sciences Investors (HQL) is $517.98M
The stock symbol (or ticker) of Tekla Life Sciences Investors is HQL
Consider the share price of Tekla Life Sciences Investors as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Tekla Life Sciences Investors has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Tekla Life Sciences Investors shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Tekla Life Sciences Investors stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Tekla Life Sciences Investors and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Tekla Life Sciences Investors stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
